Spots Global Cancer Trial Database for hsp90 inhibitor
Every month we try and update this database with for hsp90 inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas | NCT02192541 | Neoplasms | Ziv-Aflibercept Ganetespib | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | NCT00345189 | Tumors Lymphoma | CNF2024 | 18 Years - | Biogen | |
| SNX-5422 to Treat Solid Tumor Cancers and Lymphomas | NCT00644072 | Lymphoma Neoplasms | SNX-5422 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments | NCT00920205 | Cancer | MPC-3100 (an Hs... | 18 Years - | Myrexis Inc. | |
| Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma | NCT01168752 | Cancer Neoplasms Solid Tumors Lymphoma | Debio 0932 | 18 Years - | Debiopharm International SA | |
| A Study of TAS-116 in Patients With Solid Tumors | NCT02965885 | Advanced Solid ... | TAS-116 | 18 Years - | Taiho Oncology, Inc. | |
| SNX-5422 to Treat Solid Tumor Cancers and Lymphomas | NCT00644072 | Lymphoma Neoplasms | SNX-5422 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia | NCT00964873 | Acute Myeloid L... Acute Lymphobla... Blast-phase Chr... AML ALL CML | STA-9090 (ganet... | 18 Years - | Synta Pharmaceuticals Corp. | |
| HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies | NCT03906643 | Solid Tumor | HS-201 | 18 Years - 99 Years | Duke University | |
| Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | NCT00345189 | Tumors Lymphoma | CNF2024 | 18 Years - | Biogen | |
| Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL | NCT00319930 | Chronic Lymphoc... | CNF1010 (17-AAG... | 18 Years - | Biogen | |
| HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies | NCT03906643 | Solid Tumor | HS-201 | 18 Years - 99 Years | Duke University | |
| A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors | NCT00879905 | Advanced Solid ... | HSP990 | 18 Years - | Novartis | |
| HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET | NCT01668173 | Myeloproliferat... | AUY922 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| SNX-5422 to Treat Solid Tumor Cancers and Lymphomas | NCT00644072 | Lymphoma Neoplasms | SNX-5422 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas | NCT02192541 | Neoplasms | Ziv-Aflibercept Ganetespib | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
